Hypervirulent Carbapenem-resistant Klebsiella pneumoniae Infection: Epidemiology, Virulence, Resistance, and Treatment
Authors:
Open Access
- 1 September 2025
- journal article
- review article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 18, 4689-4697
Abstract
In recent years, reports of hypervirulent (hv) carbapenem-resistant (CR) Klebsiella pneumoniae (Kp) (hv-CRKp) have gradually increased. hv-CRKp may emerge from hvKp acquiring mobile genetic elements carrying multiple antibiotic-resistance genes or multi-drug-resistant Kp acquiring virulence genes, with subsequent convergence of resistance and virulence. Thus, hv-CRKp simultaneously harbors resistance and virulence genes and may even show resistance to colistin and tigecycline, suggesting potential for causing severe infections and placing a serious burden on the health care system. In this study, we review and summarize published literature on the epidemiology, virulence, resistance genes, and treatment of hv-CRKp.Keywords
This publication has 73 references indexed in Scilit:
- Clinical and laboratory insights into the threat of hypervirulent Klebsiella pneumoniaeInternational Journal of Antimicrobial Agents, 2024
- Within-host resistance evolution of a fatal ST11 hypervirulent carbapenem-resistant Klebsiella pneumoniaeInternational Journal of Antimicrobial Agents, 2023
- Characteristics of ST11 KPC‐2‐producing carbapenem‐resistant hypervirulent Klebsiella pneumoniae causing nosocomial infection in a Chinese hospitalJournal of Clinical Laboratory Analysis, 2022
- Klebsiella pneumoniae Harboring Carbapenemase Genes in Taiwan: Its Evolution over 20 Years, 1998–2019International Journal of Antimicrobial Agents, 2021
- Management of carbapenem-resistant Enterobacteriaceae infectionsClinical Microbiology and Infection, 2019
- Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infectionInternational Journal of Antimicrobial Agents, 2019
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in ChinaEBioMedicine, 2017
- Current perspectives on tigecycline resistance in Enterobacteriaceae: susceptibility testing issues and mechanisms of resistanceInternational Journal of Antimicrobial Agents, 2016
- Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K pneumoniaeAmerican Journal of Infection Control, 2012